ClinicalTrials.gg
Active, not recruitingNCT06550037OPADEUpdated May 15, 2026

Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool

An observational study in Major Depressive Disorder, sponsored by Alessio Fasano. Active, not recruiting at 1 site in Italy. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Alessio Fasano · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
350
Ages
14 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Depressive Disorder, Major with a site in Italy — 16 open to participants now, 18 under way, 6 of them phase 3. Depressive Disorder, Major · Italy.

Planned enrollment
6th of 11
350 · median 350
Started
2023
with 3 others
Observational
11 of 50
3 open now
Primary completion
2027-04
later than 9 of 17 live
Registered
39th of 50
by date
Lead sponsor
1 of 50
Alessio Fasano

Among the 50 studies in Depressive Disorder, Major with a site in Italy, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2023, is one of 11 observational ones, reaches primary completion later than 9 of the 17 other live ones, and was the 39th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

16 of the 50 studies in Depressive Disorder, Major with a site in Italy are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 14 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Depressive Disorder, Major with a site in Italy, or all of them as a file.
02

Study summary

OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD). In particular, we will combine genetics, epigenetics, microbiome, immune response data together with anamnesis, questionnaires, electroencephalography (EEG) collected from subjects suffering MDD. Eventually, an Artificial Intelligence (AI)/Machine Learning (ML) predictive tool will be created to guide clinicians in improving MDD treatment and patient's stratification.

Read the detailed description

Three hundred and fifty patients diagnosed with MDD will be enrolled for 24 months and divided into 4 groups according to age: 14-17 years (70 pediatric patients), 18-30 years (100 adult patients), 31-39 years (90 adult patients), 40-50 years (90 adult patients).

The study protocol includes 6 follow-up visits: T0 (enrollment), T1, T2, T3, T4, and T5. At each medical visit, psychometric questionnaires will be administered to the patients and contextual biological samples including blood, stool and saliva will be collected. The study will use a multi-omics approach including: metagenomic sequencing to characterize the microbiome composition; metabolomics to detect circulating metabolites; transcriptomics to quantify microRNAs; epigenomics to assess methylation variability between and within groups and immune assays to analyze the antibody immune response and inflammatory profiles (cytokines, interleukins and growth factors). Cortisol and lipoproteins will also be quantified. In parallel, cognitive assessment and emotional status will be recorded remotely by each patient via chatbot and wearable EEG devices, respectively. Specifically, the chatbot will collect patient's conversations and monitoring her/his feelings; the chat conversation will be than transformed in a machine-readable data. The EEG device is a mobile app that will also allows to associate brainwaves with patients' feelings.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorders
  • Microbiome
  • Metabolomic
  • Transcriptomics
  • Inflammation
  • Immune response profiling
  • Genetics
  • Artificial intelligence
  • Machine learning
  • Electroencephalography
  • Chatbot
  • Biomarkers
  • Personalized medicine
04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Major Depressive Disorders

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Major Depressive Disorder as certified by a SCID 5 (Structured Clinical Interview for ) for DSM-S for adults and K-SADS-PL-DSM 5 (Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime for DSM 5) for adolescents.
  • Currently experiencing a major depressive episode with a HAM-D (Hamilton Depression) score of 18 or greater, or alternatively, a MADRS (Montgomery-Asberg Depression Rating Scale) score of 18 or greater.
  • About to start a new antidepressant.
  • Not concurrently starting a new psychotropic medication.
  • Age 14-50 years.
  • Able to use mobile devices (smart phone, tablet).
  • Willingness to provide written to participate.

Exclusion criteria

Exclusion Criteria:

  • Intellectual disability.
  • Neurological disease (multiple sclerosis, severe neurocognitive disorder, epilepsy).
  • Current psychotic disorder or mood disorder with psychotic features.
  • Primary diagnosis of alcohol or substance use disorder ().
  • Patients who started concomitant psychotropic medications less than one week ago.
  • Active, ongoing inflammatory diseases (such as rheumatoid arthritis and rheumatic polymyalgia). or severe and unstable physical illness (such as recent myocardial infarction).
  • A history of or C, , or evidence of active tuberculosis infection or any active systemic infection within 2 weeks prior to the start of the study.
  • Use of antibiotics or other medications that may have affected the composition of the microbiota during the 30 days prior to baseline.
  • Pregnancy and lactation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pediatric patients affected by MDD

    14-17 years (70 pediatric patients)

  • Group 1 of adult patients affected by MDD

    18-30 years (100 adult patients)

  • Group 2 of adult patients affected by MDD

    31-39 years (90 adult patients)

  • Group 3 of adult patients affected by MDD

    40-50 years (90 adult patients)

06

What researchers measure

Primary outcomes

  1. Identify neuroinflammatory indices

    Several inflammatory markers such as G-CSF, GM-CSF, IFN-γ IL-10, IL-12p40, IL-15, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8/CXCL8, MCP-1/CCL2, TNF-α, TNFβ will be analysed.

    Time frame: 2 years

  2. Microbiome analysis

    Identification of bacterial and fungal components.

    Time frame: 2 years

  3. Metabolomic analysis

    The metabolomic analysis will involve three different groups of metabolites: 1) Intermediate of tryptophan metabolism (tryptophan, serotonin, 5-HIAA, quinurenin, quinurenic acid and other hormones and derivatives involved in the pathway) and others related to purines (paraxanthin/xanthin ratio); 2) L-acylcarnitines (including short chain, medium long-lasting acylcarnitine), with particular emphasis on laurylcarnitine and acetylcarnitine; 3) Phenolic (and related), such as phenolic acid, mandelic acid or methoxy-hydroxyphenyl glycol.

    Time frame: 2 years

  4. Analysis of lipoprotein profile

    Different forms of lipoproteins will be evaluated: Apolipoproteins A1 and A2, HDL-apolipoproteins A1 and A2,free cholesterol HDL3, HDL3-apolipoprotein A1, HDL2-apolipoprotein A2, apolipoprotein A2, IDL, HDL-apolipoprotein A2, VLDL and its subtypes, VLDL2-triglycerides, VLDL3-triglyceridestriglycerides, VLDL2- cholesterol, VLDL3 cholesterol, VLDL4 cholesterol free of VLDL4, phospholipids VLDL2, Phospholipids VLDL3, Cholesterol LDL5, Cholesterol free LDL5, Phospholipids LDL5, LDL5-apolipoprotein B, HDL3 cholesterol, HDL4 cholesterol HDL4, HDL3 cholesterol free, free cholesterol HDL4, HDL3-phospholipids, HDL4-phospholipids, HDL3-apolipoprotein A1, HDL4-apolipoprotein A1, HDL3-apolipoprotein A2 and HDL4-apolipoprotein A2.

    Time frame: 2 years

  5. Identify immune-profile linked and epigenomic signatures

    Methylome analysis on genomic DNA will be performed.

    Time frame: 2 years

  6. AI-powered diagnostics predictive tool (companion diagnostic-like)

    Deploy an AI-powered predictive tool (companion diagnostic-like) in clinical practice for the prescription of anti-depressants. OPADE AI-powered predictive tool will be a class C medical device under the In vitro diagnostic classification.

    Time frame: 2 years

  7. Mood assessment through brain biomarker

    Validate a patient tracking tool for mood assessment using brain biomarker.

    Time frame: 2 years

  8. Patient engagement digital tool

    Validate a patient engagement digital tool that can be deployed in any patient community to enhance clinical study outcomes.

    Time frame: 2 years

  9. Discovery of a new set of biomarkers

    Propose new set of biomarkers that can guide the development of new antidepressants

    Time frame: 2 years

  10. Investigation of the gut-brain-axis and of the biomarkers of interest in the context of mental diseases starting with MDD

    Identify indices in MDD to improve diagnostic accuracy for primary prevention and patients' stratification.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 44 months after the start.

Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 44 months is close to that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Aug 12, 2024
StartActual
Aug 7, 2023
Primary completionEst.
Apr 2027
CompletionEst.
May 31, 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550037
Lead sponsor
Alessio Fasano
Collaborators
University of Siena, Fundació Eurecat, Perseus Biomics, ARTIFICIAL INTELLIGENCE EXPERT SRL, Mama Health Technologies GmbH, Protobios OU, Cephalgo, Biokeralty Research Institute, Sanitas University, Accare, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Istanbul Medipol University Hospital, CEINGE, Fondazione di ricerca biomedica EBRIS
Responsible party
Alessio Fasano (Clinical Director, Massachusetts General Hospital) — Sponsor-investigator
First posted
Aug 12, 2024
Start date
Aug 7, 2023
Primary completion
Apr 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion